caprotec bioanalytics launches new kits for proteomics and drug
5 February 2010
Berlin-based caprotec bioanalytics has launched three new
caproKits, for the discovery, identification and characterization of
proteins belonging to the groups of metallo-proteases,
histon-deacetylases and GDP/GTP binding proteins.
The three new kits are the Marimastat caproKit, SAHA caproKit and GDP
caproKit, respectively and increase the number of commercially available
caproKits to a total of seven.
The company's caproKits are based on the proprietary Capture Compound
Mass Spectrometry (CCMS) technology, a novel and direct way to
investigate small molecule–protein interactions resulting in a
significant functional reduction of proteome complexity. Capture
Compounds enable direct isolation and identification of proteins
including membrane proteins out of complex biological samples.
The new and existing kits target different areas of research ranging
from signal transduction (cAMP, cGMP, Stauro and the new GDP caproKit)
to epigenetics (SAH and the new SAHA caproKit), and proteases (Marimastat
caproKit). Additional caproKits for applications in these and other
research areas are under development and will be released in the coming
"Our new caproKits are innovative and effective tools for researchers
in the field of proteomics needing a solution for targeted reduction of
sample complexity," stated Dr. Hubert Koster, CEO of caprotec
bioanalytics. "Our most recent scientific publications in Molecular and
Cellular Proteomics and Toxicological Sciences provide powerful
testimonials for the capabilities of our CCMS technology."